Oncolytics Biotech (ONCY) Current Leases (2019 - 2026)

Oncolytics Biotech (ONCY) has reported Current Leases for 8 consecutive years, with $138000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Leases fell 67.97% year-over-year to $138000.0 in Q2 2026; TTM through Jun 2026 was $138000.0, a 67.97% decrease from a year earlier, with the FY2025 full-year figure at $193000.0, down 3.5% from the prior year.
• Current Leases was $138000.0 for Q2 2026 at Oncolytics Biotech, down from $193000.0 in the prior quarter.
• Over five years, Current Leases peaked at $703523.3 in Q1 2024 and troughed at $115662.4 in Q4 2022.
• A 5-year average of $339929.8 and a median of $257580.6 in 2023 frame the typical range for Current Leases.
• Across the five-year window, Current Leases jumped 164.48% in 2024 and slumped 67.97% in 2026, its largest moves.
• Over 5 years, Current Leases stood at $115662.4 in 2022, then jumped by 84.17% to $213015.3 in 2023, then jumped by 164.48% to $563373.3 in 2024, then tumbled by 65.74% to $193000.0 in 2025, then fell by 28.5% to $138000.0 in 2026.
• The last three Current Leases figures came in at $138000.0 (Q2 2026), $193000.0 (Q4 2025), and $404735.7 (Q3 2025), per Business Quant data.